## John J Atherton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8268747/publications.pdf

Version: 2024-02-01

7511 81839 28,724 167 39 151 citations h-index g-index papers 171 171 171 29390 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	1.0	13,008
2	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
3	Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy and Conduction-System Disease. New England Journal of Medicine, 1999, 341, 1715-1724.	13.9	1,195
4	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 807-816.	6.3	934
5	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure. 2021. 23, 352-380.	2.9	630
6	A Prospective Study of Sudden Cardiac Death among Children and Young Adults. New England Journal of Medicine, 2016, 374, 2441-2452.	13.9	619
7	Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nature Genetics, 2002, 30, 201-204.	9.4	526
8	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 2021, 384, 105-116.	13.9	381
9	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	0.7	362
10	Effect of Levosimendan on the Short-TermÂClinical Course of Patients With AcutelyÂDecompensated Heart Failure. JACC: Heart Failure, 2013, 1, 103-111.	1.9	337
11	Hierarchical layered double hydroxide nanocomposites: structure, synthesis and applications. Chemical Communications, 2015, 51, 3024-3036.	2.2	322
12	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal, 2017, 38, 1119-1127.	1.0	285
13	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung and Circulation, 2018, 27, 1123-1208.	0.2	262
14	Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage. Journal of the American College of Cardiology, 2000, 36, 1328-1335.	1.2	213
15	Diastolic ventricular interaction in chronic heart failure. Lancet, The, 1997, 349, 1720-1724.	6.3	203
16	Heart Failure Care in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. PLoS Medicine, 2014, 11, e1001699.	3.9	198
17	Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Diabetes Care, 2018, 41, 69-78.	4.3	195
18	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	1.0	195

#	Article	IF	CITATIONS
19	Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine, 2019, 381, 716-726.	13.9	174
20	Patient Characteristics From a Regional Multicenter Database of Acute Decompensated Heart Failure in Asia Pacific (ADHERE International–Asia Pacific). Journal of Cardiac Failure, 2012, 18, 82-88.	0.7	155
21	Nonfamilial Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	141
22	2011 Update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Medical Journal of Australia, 2011, 194, 405-409.	0.8	128
23	Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Medical Journal of Australia, 2006, 185, 549-556.	0.8	122
24	A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart, 2012, 98, 625-630.	1.2	119
25	Rationale and design of the <scp>SOluble</scp> guanylate Cyclase <scp>stimulatoR</scp> in <scp>heArT failurE</scp> Studies ( <scp>SOCRATES</scp> ). European Journal of Heart Failure, 2014, 16, 1026-1038.	2.9	119
26	Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genetics in Medicine, 2013, 15, 972-977.	1.1	110
27	Differences in management and outcomes for men and women with STâ€elevation myocardial infarction. Medical Journal of Australia, 2018, 209, 118-123.	0.8	106
28	Antisenseâ€mediated exon skipping: a therapeutic strategy for titinâ€based dilated cardiomyopathy. EMBO Molecular Medicine, 2015, 7, 562-576.	3.3	94
29	Arg389Gly- $\hat{1}^21$ -adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and Genomics, 2007, 17, 941-949.	0.7	78
30	Ventricular interaction and external constraint account for decreased stroke work during volume loading in CHF. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H2385-H2391.	1.5	73
31	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet, The, 2022, 399, 1391-1400.	6.3	67
32	Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy. Journal of Molecular Medicine, 2006, 84, 478-483.	1.7	64
33	Failure of Reflex Venoconstriction During Exercise in Patients With Vasovagal Syncope. Circulation, 1996, 93, 953-959.	1.6	62
34	Endothelium-Derived Nitric Oxide Contributes to the Regulation of Venous Tone in Humans. Circulation, 2000, 101, 165-170.	1.6	57
35	Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. British Journal of Clinical Pharmacology, 2005, 59, 281-290.	1.1	57
36	NT-ProBNP Levels in Saliva and Its Clinical Relevance to Heart Failure. PLoS ONE, 2012, 7, e48452.	1.1	48

#	Article	IF	CITATIONS
37	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: ⟨scp⟩GALACTICâ€HF⟨/scp⟩ baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	2.9	47
0.0	Effect of a Telephone-Delivered Coronary Heart Disease Secondary Prevention Program (ProActive) Tj ETQq0 0 C	0	
38	International Journal of Behavioral Medicine, 2013, 20, 413-424.	0.8	45
39	Diastolic Dysfunction Assessed Using Contemporary Guidelines and Prognosis Following Myocardial Infarction. Journal of the American Society of Echocardiography, 2018, 31, 1127-1136.	1.2	44
40	Health status of cardiac genetic disease patients and their at-risk relatives. International Journal of Cardiology, 2013, 165, 448-453.	0.8	43
41	Discordance between level of risk and intensity of evidenceâ€based treatment in patients with acute coronary syndromes. Medical Journal of Australia, 2007, 187, 153-159.	0.8	42
42	Reduced Cardiopulmonary Baroreflex Sensitivity in Patients With Hypertrophic Cardiomyopathy 11Drs. Frenneaux, Morris-Thurgood and Atherton were supported by the British Heart Foundation, London. This study was supported in part by Project Grant 665 941193 and Scholarship Grant 948220 from the NH&MRC of Australia Journal of the American College of Cardiology, 1998, 31, 1377-1382.	1,2	39
43	Screening for Left Ventricular Systolic Dysfunction: Is Imaging a Solution?. JACC: Cardiovascular Imaging, 2010, 3, 421-428.	2.3	39
44	Predictors of physical and mental health-related quality of life outcomes among myocardial infarction patients. BMC Cardiovascular Disorders, 2013, 13, 69.	0.7	38
45	Restrictive Left Ventricular Filling Patterns Are Predictive of Diastolic Ventricular Interaction in Chronic Heart Failure. Journal of the American College of Cardiology, 1998, 31, 413-418.	1.2	37
46	Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart, 1999, 82, 8iii-15.	1.2	37
47	Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population. European Journal of Hybrid Imaging, 2018, 2, 17.	0.6	36
48	Abnormal Forearm Vascular Responses During Dynamic Leg Exercise in Patients With Vasovagal Syncope. Circulation, 1995, 92, 2204-2209.	1.6	36
49	Addition of Supervised Exercise Training to a Post-Hospital Disease Management Program for Patients Recently HospitalizedÂWith Acute Heart Failure. JACC: Heart Failure, 2018, 6, 143-152.	1.9	35
50	Individualized Compared With Conventional Dosing of Enoxaparin. Clinical Pharmacology and Therapeutics, 2008, 83, 882-888.	2.3	34
51	Telephone-delivered health coaching improves anxiety outcomes after myocardial infarction: the â€ <sup>-</sup> ProActive Heart' trial. European Journal of Preventive Cardiology, 2014, 21, 30-38.	0.8	33
52	International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. American Heart Journal, 2012, 163, 804-811.	1,2	32
53	Efficacy and Feasibility of a Tele-health Intervention for Acute Coronary Syndrome Patients with Depression: Results of the "MoodCare―Randomized Controlled Trial. Annals of Behavioral Medicine, 2014, 48, 163-174.	1.7	32
54	Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. European Journal of Preventive Cardiology, 2015, 22, 1111-1120.	0.8	32

#	Article	lF	CITATIONS
55	Diastolic Ventricular Interaction. Circulation, 1997, 96, 4273-4279.	1.6	32
56	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018. Medical Journal of Australia, 2018, 209, 363-369.	0.8	31
57	Improving medication titration in heart failure by embedding a structured medication titration plan. International Journal of Cardiology, 2016, 224, 99-106.	0.8	30
58	The Pre-Test Risk Stratified Cost-Effectiveness of 64-Slice Computed Tomography Coronary Angiography in the Detection of Significant Obstructive Coronary Artery Disease in Patients Otherwise Referred to Invasive Coronary Angiography. Heart Lung and Circulation, 2009, 18, 200-207.	0.2	29
59	Prescribing and up-titration in recently hospitalized heart failure patients attending a disease management program. International Journal of Cardiology, 2016, 216, 121-127.	0.8	27
60	Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial. Circulation, 2022, 145, 1443-1455.	1.6	27
61	Genetic testing for inherited heart diseases: longitudinal impact on health-related quality of life. Genetics in Medicine, 2012, 14, 749-752.	1.1	26
62	Reflex Responses of Venous Capacitance Vessels in Patients with Hypertrophic Cardiomyopathy. Clinical Science, 1998, 94, 339-346.	1.8	25
63	A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva. Journal of Clinical Pathology, 2016, 69, 1100-1104.	1.0	25
64	Expert Comment: Is Medication Titration in Heart Failure too Complex?. Cardiac Failure Review, 2017, 03, 25.	1.2	25
65	Guidelines for the Diagnosis and Management of Hypertrophic Cardiomyopathy. Heart Lung and Circulation, 2007, 16, 16-18.	0.2	23
66	Exercise training in recently hospitalized heart failure patients enrolled in a disease management programme: design of the EJECTION-HF randomized controlled trial. European Journal of Heart Failure, 2011, 13, 1370-1375.	2.9	23
67	A randomised, feasibility trial of a tele-health intervention for Acute Coronary Syndrome patients with depression ('MoodCare'): Study protocol. BMC Cardiovascular Disorders, 2011, 11, 8.	0.7	23
68	Diastolic stress echocardiography: from basic principles to clinical applications. Heart, 2018, 104, 1739-1748.	1.2	23
69	Circulating Fragments of N-Terminal Pro–B-Type Natriuretic Peptides in Plasma of Heart Failure Patients. Clinical Chemistry, 2013, 59, 1523-1531.	1.5	22
70	Quantification of D-dimer levels in human saliva. Bioanalysis, 2013, 5, 2249-2256.	0.6	21
71	Psychosocial Implications of Living with Catecholaminergic Polymorphic Ventricular Tachycardia in Adulthood. Journal of Genetic Counseling, 2018, 27, 549-557.	0.9	21
72	Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment. Cardio-Oncology, 2017, 3, 6.	0.8	20

#	Article	IF	Citations
73	Assessment of myocardial oxygenation, strain, and diastology in MYBPC3-related hypertrophic cardiomyopathy: a cardiovascular magnetic resonance and echocardiography study. European Heart Journal Cardiovascular Imaging, 2019, 20, 932-938.	0.5	20
74	Modelling the occurrence and severity of enoxaparinâ€induced bleeding and bruising events. British Journal of Clinical Pharmacology, 2009, 68, 700-711.	1.1	19
75	TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: a randomised clinical trial protocol. BMJ Open, 2018, 8, e019463.	0.8	19
76	Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study. European Journal of Heart Failure, 2018, 20, 474-480.	2.9	19
77	Secondary prevention therapies in acute coronary syndrome and relation to outcomes: observational study. Heart Asia, 2019, 11, e011122.	1.1	19
78	Identification and Validation of a Salivary Protein Panel to Detect Heart Failure Early. Theranostics, 2017, 7, 4350-4358.	4.6	18
79	Quality of care of patients hospitalized with congestive heart failure. Internal Medicine Journal, 2003, 33, 140-151.	0.5	17
80	New Diastology Guidelines: Evolution, Validation and Impact on Clinical Practice. Heart Lung and Circulation, 2019, 28, 1411-1420.	0.2	17
81	COVID-19 and Acute Heart Failure: Screening the Critically III – A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ). Heart Lung and Circulation, 2020, 29, e94-e98.	0.2	17
82	The Use of Mobile Apps for Heart Failure Self-management: Systematic Review of Experimental and Qualitative Studies. JMIR Cardio, 2022, 6, e33839.	0.7	17
83	Randomised controlled trial of a secondary prevention program for myocardial infarction patients ('ProActive Heart'): study protocol. BMC Cardiovascular Disorders, 2009, 9, 16.	0.7	16
84	Relation of Left Atrial Volumes in Patients With Myocardial Infarction to Left Ventricular Filling Pressures and Outcomes. American Journal of Cardiology, 2019, 124, 325-333.	0.7	16
85	Effect of a mindfulness programme for longâ€ŧerm care residents with type 2 diabetes: A cluster randomised controlled trial measuring outcomes of glycaemic control, relocation stress and depression. International Journal of Older People Nursing, 2020, 15, e12312.	0.6	16
86	Amyloid Cardiomyopathy. Heart Lung and Circulation, 2020, 29, 575-583.	0.2	15
87	Implications of the Obesity Epidemic for Statin Therapy: Shifting Cholesterol Metabolism to a High Synthesis and Low Dietary Absorption State. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2007, 7, 153-166.	0.6	14
88	Individualized Dosing of Enoxaparin for Subjects With Renal Impairment Is Superior to Conventional Dosing at Achieving Therapeutic Concentrations. Therapeutic Drug Monitoring, 2010, 32, 482-488.	1.0	14
89	Cardiotoxicity after cancer treatment: a process map of the patient treatment journey. Cardio-Oncology, 2019, 5, 14.	0.8	14
90	Nutraceuticals in Patients With Heart Failure: A Systematic Review. Journal of Cardiac Failure, 2020, 26, 166-179.	0.7	14

#	Article	IF	CITATIONS
91	Establishment of an Australian National Genetic Heart Disease Registry. Heart Lung and Circulation, 2008, 17, 463-467.	0.2	13
92	The potential prognostic utility of salivary galectin-3 concentrations in heart failure. Clinical Research in Cardiology, 2020, 109, 685-692.	1.5	13
93	Diastolic ventricular interaction in chronic heart failure: relation to heart rate variability and neurohumoral status. Heart and Vessels, 1998, 13, 269-277.	0.5	12
94	Biventricular diastolic behaviour in patients with hypertrophic and hereditary hemochromatosis cardiomyopathies. European Journal of Echocardiography, 2004, 5, 356-366.	2.3	12
95	Stage B Heart Failure: Rationale for Screening. Heart Failure Clinics, 2012, 8, 273-283.	1.0	12
96	Risk-Factor Profile and Comorbidities in 2398 Patients With Newly Diagnosed Hypertension From the Abuja Heart Study. Medicine (United States), 2015, 94, e1660.	0.4	12
97	Rarity and phenotypic heterogeneity provide challenges in the diagnosis of Andersen–Tawil syndrome: Two cases presenting with ECGs mimicking catecholaminergic polymorphic ventricular tachycardia (CPVT). International Journal of Cardiology, 2015, 201, 473-475.	0.8	12
98	Right Ventricular Systolic Dysfunction Is Common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa. PLoS ONE, 2016, 11, e0153479.	1.1	12
99	Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. European Heart Journal Quality of Care & Dutcomes, 2018, 4, 309-317.	1.8	12
100	Development and feasibility testing of an education program to improve knowledge and self-care among Aboriginal and Torres Strait Islander patients with heart failure. Rural and Remote Health, 2015, 15, 3231.	0.4	12
101	Position Statement on the Diagnosis and Management of Familial Dilated Cardiomyopathy. Heart Lung and Circulation, 2017, 26, 1127-1132.	0.2	11
102	Sodiumâ€glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review. ESC Heart Failure, 2021, 8, 4093-4118.	1.4	11
103	Technology-Assisted Congestive Heart Failure Care. Current Heart Failure Reports, 2015, 12, 173-186.	1.3	10
104	Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis. Internal Medicine Journal, 2016, 46, 1297-1306.	0.5	10
105	Impact of the implantable cardioverter defibrillator on confidence to undertake physical activity in inherited heart disease: A cross-sectional study. European Journal of Cardiovascular Nursing, 2017, 16, 742-752.	0.4	10
106	Cardiac myosin-binding protein C gene mutation expressed as hypertrophic cardiomyopathy and left ventricular noncompaction within two families: Insights from cardiac magnetic resonance in clinical screening. International Journal of Cardiology, 2013, 168, 2950-2952.	0.8	9
107	Primary Carnitine Deficiency: A Rare, Reversible Metabolic Cardiomyopathy. Case Reports in Cardiology, 2018, 2018, 1-3.	0.1	9
108	Treatment with incretins does not increase the risk of pancreatic diseases compared to older antiâ€hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. Diabetic Medicine, 2019, 36, 491-498.	1.2	9

#	Article	IF	CITATIONS
109	A lethal injection?. Lancet, The, 2012, 379, 492.	6.3	8
110	Protocol for a randomised blocked design study using telephone and text-messaging to support cardiac patients with diabetes: a cross cultural international collaborative project. BMC Health Services Research, 2013, 13, 402.	0.9	8
111	The addition of depression to the Framingham Risk Equation model for predicting coronary heart disease risk in women. Preventive Medicine, 2016, 87, 115-120.	1.6	8
112	Cardiovascular Telemedicine Program in Rural Australia. New England Journal of Medicine, 2020, 383, 883-884.	13.9	8
113	Left Ventricular Diastolic Function in Normotensive Type-2 Diabetic Subjects. Journal of the National Medical Association, 2008, 100, 1066-1072.	0.6	7
114	Chronic Heart Failure: We Are Fighting the Battle, but Are We Winning the War?. Scientifica, 2012, 2012, 1-16.	0.6	7
115	Characteristics of patients with haematological and breast cancer (1996–2009) who died of heart failureâ€related causes after cancer therapy. ESC Heart Failure, 2016, 3, 253-260.	1.4	7
116	Salivary Protein Panel to Diagnose Systolic Heart Failure. Biomolecules, 2019, 9, 766.	1.8	7
117	Hypertrophic Cardiomyopathy: Challenging the Status Quo?. Heart Lung and Circulation, 2020, 29, 556-565.	0.2	7
118	A multimarker approach to diagnose and stratify heart failure. International Journal of Cardiology, 2015, 181, 369-375.	0.8	6
119	Left Ventricular Systolic Dysfunction in Asymptomatic Black Hypertensive Subjects. American Journal of Hypertension, 2015, 28, 924-929.	1.0	6
120	Echocardiographic predictors of all-cause mortality in patients with left ventricular ejection fraction >35%: Value of guideline based assessment of diastolic dysfunction. IJC Heart and Vasculature, 2019, 24, 100407.	0.6	6
121	Hemodynamic Validation of the E/e' Ratio as a Measure of Left Ventricular Filling Pressure in Patients With Non-ST Elevation Myocardial Infarction. American Journal of Cardiology, 2020, 125, 507-512.	0.7	6
122	Demonstration of late cardiotoxicity following bone marrow transplantation by assessment of exercise diastolic filling characteristics. Bone Marrow Transplantation, 1996, 17, 1113-8.	1.3	6
123	Usefulness of right ventricular myocardial strain in assessment of response to thrombolytic therapy in acute pulmonary embolism. European Journal of Echocardiography, 2010, 11, 892-895.	2.3	5
124	Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?. Cardiac Failure Review, 2016, 2, 47.	1.2	5
125	Eustachian valve endocarditis: Case report and literature review. Australasian Journal of Ultrasound in Medicine, 2018, 21, 29-35.	0.3	5
126	AUSTRALIAN PATIENTS USING A CARDIAC-DIABETES WEB-BASED INTERVENTION PROGRAM: CONTRIBUTIONS TO PERSON-CENTERED CLINICAL PRACTICE. European Journal for Person Centered Healthcare, 2015, 3, 168.	0.3	5

#	Article	IF	Citations
127	Forearm vascular responses during semierect dynamic leg exercise in patients following myocardial infarction. Heart and Vessels, 1998, 13, 87-94.	0.5	4
128	Forearm vasoconstriction during dynamic leg exercise in patients with chronic heart failure. Heart and Vessels, 1998, 13, 278-289.	0.5	4
129	The role of diastolic ventricular interaction in abnormal cardiac baroreflex function in chronic heart failure. Australian and New Zealand Journal of Medicine, 1999, 29, 428-432.	0.5	4
130	Prevalence of dyslipidemia in normoglycemic subjects with newly diagnosed high blood pressure in Abuja, Nigeria. Journal of Clinical Lipidology, 2009, 3, 51-56.	0.6	4
131	Cardiacâ€diabetes selfâ€management program for Australians and Taiwanese: A randomized blocked design study. Australian Journal of Cancer Nursing, 2017, 19, 307-315.	0.8	4
132	Patients With Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement. Heart Lung and Circulation, 2020, 29, e85-e87.	0.2	4
133	Evaluation of training nurses to perform semiâ€automated threeâ€dimensional left ventricular ejection fraction using a customised workstationâ€based training protocol. Journal of Clinical Nursing, 2015, 24, 1479-1488.	1.4	3
134	Heart failure following blood cancer therapy in pediatric and adult populations. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 224-230.	0.7	3
135	Hyponatraemia in heart failure. Internal Medicine Journal, 2020, 50, 659-666.	0.5	3
136	Evolutionary dissection of mtDNA hg H: a susceptibility factor for hypertrophic cardiomyopathy. Mitochondrial DNA Part A: DNA Mapping, Sequencing, and Analysis, 2020, 31, 238-244.	0.7	3
137	Determinants of Diastolic Dysfunction Following Myocardial Infarction: Evidence for Causation Beyond InfarctÂSize. Heart Lung and Circulation, 2020, 29, 1815-1822.	0.2	3
138	Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines. Current Cardiology Reviews, 2016, 12, 166-179.	0.6	3
139	A Unique Presentation of Antiphospholipid Antibody Syndrome in Pregnancy. Heart Lung and Circulation, 2005, 14, 87-89.	0.2	2
140	NON-FAMILIAL HYPERTROPHIC CARDIOMYOPATHY: PREVALENCE, NATURAL HISTORY AND CLINICAL IMPLICATIONS. Journal of the American College of Cardiology, 2017, 69, 839.	1.2	2
141	The Cardiac Society of Australia and New Zealand Position Statement on the Diagnosis and Management of Arrhythmogenic Right Ventricular Cardiomyopathy (2019 Update). Heart Lung and Circulation, 2020, 29, 40-48.	0.2	2
142	Accuracy of Cardiac Nurse Acquired and Measured Three-Dimensional Echocardiographic Left Ventricular Ejection Fraction: Comparison to Echosonographer. Heart Lung and Circulation, 2020, 29, 703-709.	0.2	2
143	Investigation of current models of care for genetic heart disease in Australia: A national clinical audit. International Journal of Cardiology, 2021, 330, 128-134.	0.8	2
144	Mechanisms of exercise limitation in chronic heart failure and the role of rehabilitation. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 731-734.	0.2	1

#	Article	IF	CITATIONS
145	Striving to achieve best practice in heart failure disease management. BMJ Quality and Safety, 2012, 21, 263-263.	1.8	1
146	Clinical cases from the ESC Cardiologists of Tomorrow. European Heart Journal, 2016, 37, 1409-1427.	1.0	1
147	Myofibrillar Cardiomyopathy due to a Novel Desmin Gene Mutation: Complementary Role of Echocardiography, Cardiac Magnetic Resonance, and Genetic Testing in Delineating Diagnosis. Case, 2017, 1, 28-33.	0.1	1
148	Effectiveness of the cardiac-diabetes transcare program: protocol for a randomised controlled trial. BMC Health Services Research, 2017, 17, 109.	0.9	1
149	Response to "Paradise Lost? New National Heart Foundation of Australia Guidelines on Heart Failure Fail to Recognise the Intensity of Exercise Evidenceâ€, Heart Lung and Circulation, 2020, 29, e9.	0.2	1
150	Genetic Cardiovascular Conditions–Âlt'sÂAll About Family. Heart Lung and Circulation, 2020, 29, 495-497.	0.2	1
151	Sex Differences in Baseline Characteristics Do Not Predict Early Outcomes after Percutaneous Coronary Intervention: Results from the Australian GenesisCare Cardiovascular Outcomes Registry (GCOR). Journal of Clinical Medicine, 2022, 11, 1138.	1.0	1
152	Best Practice for Australian Chronic Heart Failure Management Programs: Strategic Positioning for Health Service Quality and Expansion. Journal of Cardiac Failure, 2010, 16, S91.	0.7	0
153	International Variation in Use of Anticoagulation among Heart Failure Patients with Atrial Fibrillation. Journal of Cardiac Failure, 2011, 17, S72.	0.7	0
154	Addressing Health Literacy and Cultural Teaching Issues in Australian Indigenous and Non-indigenous Heart Failure Patients Using Avatars: Technology Development and Pilot Testing. Journal of Cardiac Failure, 2014, 20, S115.	0.7	0
155	Cardiotoxicity following Cancer Treatment: Linked Health Data Analysis. Journal of Cardiac Failure, 2014, 20, S99.	0.7	0
156	Death Analysis of a Cohort of Blood, Lymphatic Cancer and Breast Cancer Patients Who Have Developed Heart Failure Following Cancer Treatment. Journal of Cardiac Failure, 2015, 21, S55.	0.7	0
157	Cardiotoxicity after Cancer Treatment: Comparing Clinical Practice with Guidelines. Journal of Cardiac Failure, 2018, 24, S8.	0.7	0
158	Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?. Diabetes Therapy, 2019, 10, 1625-1643.	1.2	0
159	Should patients with heart failure listen to their gut?. Medical Journal of Australia, 2020, 213, 357-358.	0.8	0
160	A COMPOSITE ECHOCARDIOGRAPHIC SCORE TO PREDICT LONG-TERM SURVIVAL FOLLOWING MYOCARDIAL INFARCTION. Journal of the American College of Cardiology, 2020, 75, 1668.	1.2	0
161	Hemodynamic and Prognostic Validation of Novel Combined Algorithm to Assess Diastolic Function and Filling Pressures. JACC: Cardiovascular Imaging, 2020, 13, 2275-2276.	2.3	0
162	Clarification of the Australian heart failure guideline recommendation for primary prevention defibrillator implantation in nonâ€ischaemic cardiomyopathy. Medical Journal of Australia, 2020, 212, 509.	0.8	0

## JOHN J ATHERTON

#	Article	IF	CITATIONS
163	Development of a preference-based heart disease-specific health state classification system using MacNew heart disease-related quality of life instrument. Quality of Life Research, 2022, 31, 257-268.	1.5	O
164	Quality first in obstructive hypertrophic cardiomyopathy. Lancet, The, 2021, 397, 2440-2441.	6.3	0
165	Ten-Year Coronary Artery Disease Risk in 1571 Newly Presenting Hypertensive Black Subjects., 2016, 6, .		O
166	Management of angina. Australian Family Physician, 1994, 23, 2325-34.	0.5	0
167	Composite Echocardiographic Score to Predict Long-Term Survival Following Myocardial Infarction. Heart Lung and Circulation, 2022, , .	0.2	0